Mesa Laboratories (NASDAQ:MLAB) CAO Sells $39,559.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen sold 442 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares in the company, valued at approximately $180,790. This represents a 17.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyndsey Elizabeth Crennen also recently made the following trade(s):

• On Tuesday, June 16th, Lyndsey Elizabeth Crennen sold 118 shares of Mesa Laboratories stock. The shares were sold at an average price of $101.27, for a total value of $11,949.86.

Mesa Laboratories Price Performance

Shares of Mesa Laboratories stock traded down $0.03 during mid-day trading on Tuesday, reaching $93.20. 104,033 shares of the stock were exchanged, compared to its average volume of 138,588. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The company has a market cap of $514.93 million, a price-to-earnings ratio of 77.67 and a beta of 0.94. Mesa Laboratories, Inc. has a fifty-two week low of $55.45 and a fifty-two week high of $113.99. The firm has a 50-day simple moving average of $101.95 and a 200 day simple moving average of $90.98.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The firm had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter last year, the firm posted ($1.31) EPS.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were paid a $0.16 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. Mesa Laboratories’s payout ratio is currently 53.33%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Mason Capital Management LLC bought a new stake in Mesa Laboratories during the 3rd quarter worth about $4,711,000. Crawford Investment Counsel Inc. boosted its stake in shares of Mesa Laboratories by 59.4% in the 3rd quarter. Crawford Investment Counsel Inc. now owns 82,467 shares of the medical instruments supplier’s stock valued at $5,526,000 after purchasing an additional 30,723 shares during the last quarter. Roubaix Capital LLC acquired a new stake in shares of Mesa Laboratories during the 3rd quarter worth approximately $5,137,000. Gabelli Funds LLC raised its stake in shares of Mesa Laboratories by 114.6% during the third quarter. Gabelli Funds LLC now owns 53,974 shares of the medical instruments supplier’s stock worth $3,617,000 after buying an additional 28,818 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. raised its stake in shares of Mesa Laboratories by 15.1% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 141,973 shares of the medical instruments supplier’s stock worth $11,145,000 after buying an additional 18,592 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.